Robust anti-tubercular profile of Solanum virginianum extract in enhancing isoniazid bioavailability and curtailing stress tolerance in Mycobacterium smegmatis
Authors
Acharya Balkrishna
Drug Discovery and Development Division, Patanjali Research Foundation, Haridwar, Uttarakhand, India
Monali Joshi
Drug Discovery and Development Division, Patanjali Research Foundation, Haridwar, Uttarakhand, India
Manisha Kabdwal
Drug Discovery and Development Division, Patanjali Research Foundation, Haridwar, Uttarakhand, India
Meenu Tomer
Drug Discovery and Development Division, Patanjali Research Foundation, Haridwar, Uttarakhand, India
Savita Lochab
Drug Discovery and Development Division, Patanjali Research Foundation, Haridwar, Uttarakhand, India
Anurag Varshney
Drug Discovery and Development Division, Patanjali Research Foundation, Haridwar, Uttarakhand, India
Keywords:
mc 2155, isoniazid, adjunct therapy, tuberculosis, stress tolerance, targeted metabolomics
Abstract
Introduction
The formidable survival mechanisms employed by Mycobacterium tuberculosis (Mtb), combined with the low bioavailability of anti-tubercular drugs and their associated hepatotoxicity, worsen tuberculosis management. Traditional medicinal plants offer potential solutions to these challenges. This study focuses on exploring the anti-tubercular potential of Solanum virginianum against Mycobacterium smegmatis, mc2155.
Methods and results
HPTLC and UHPLC phytochemically characterized the hydro-methanolic extract of Solanum virginianum (SVE). SVE curtails the growth and viability of mc2155 under normal and in vitro stress conditions. The compromised cell wall integrity of mc2155 with SVE is depicted through scanning electron microscopy (SEM) while EtBr permeability assays and TLC-based comparative changes in lipids extraction addressed the integrity of the cell wall. Furthermore, SVE augmented the susceptibility of mc2155 towards Isoniazid (INH) through enhanced bioavailability. Adjunct treatment of SVE with INH demonstrated a markedly reduced survival of the intracellular bacilli. The study also uncovered the hepatoprotective potential of SVE in HepG2 cells.
Conclusion
This research paves the way for deeper exploration into the potential of Solanum virginianum against virulent Mtb strains, emphasizing over the significance of traditional medicinal plants in tuberculosis treatment. Collectively, the findings suggest SVE as a potent candidate for independent or adjunct anti-tubercular therapy.
Keywords: mc 2155 , isoniazid, adjunct therapy, tuberculosis, stress tolerance, targeted metabolomics
Author Biographies
Acharya Balkrishna, Drug Discovery and Development Division, Patanjali Research Foundation, Haridwar, Uttarakhand, India
Vedic Acharya Samaj Foundation, Inc., Groveland, FL, United States
Anurag Varshney, Drug Discovery and Development Division, Patanjali Research Foundation, Haridwar, Uttarakhand, India
Special Centre for Systems Medicine, Jawaharlal Nehru University, New Delhi, India
Click on "Archives" to access the full archive of scientific preprints. You may use the categories and the search functionality to find select preprints you're interested in.
